Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Biotechnology

Healthcare
$2.43 +2.06%

+$0.05 today

Market cap
$309.51M
Beta
0.75
P/E (TTM)
-4.9
EPS (TTM)
-$0.45
52W Low $0.62High $4.31

Volume 4.55M

Average 0.40M

NAUT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Nautilus Biotechnology, Inc.NASDAQ: NAUT

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $1.48M fell 9.2% year over year, ahead of the -43.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.

Context

  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -9.2% holds above the trailing-twelve-month pace of -43.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.48M-7.1% QoQ
Last fiscal yearDec 2025
$6.47M+1.8% YoY
LTMMar 2026
$6.32M-43.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.2%——
1 year+1.8%——
3-year CAGR+23.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
6.47M USD
Year-over-year change
+1.8%
4-year CAGR
+22.8%

Cost of Revenue vs competitors

How NAUT compares with its peers on the latest reported figures

  • NAUT's LTM Mar 2026 cost of revenue of $6.32M is the 4th highest of the 11 companies compared; the peer median is $1M.
  • Its year-over-year change of -43.5% is the 4th highest of 6, against a peer median of +85.4%.
  • Over three fiscal years its annual growth of +23.7% compares with a peer median of +13.1%.
NAUT Competitors Peer median
Cost of Revenue for NAUT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$21.94M ——77.7%
HUMAHumacyte, Inc.LTM Mar 2026$17.11M +85.4%+27.3%848.5%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$16.18M -62.1%-87.7%22.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.32M -43.5%+23.7%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M ——8.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.21M ——1.7%
IMRXImmuneering CorporationLTM Mar 2026$793.21K +354.2%+64.1%—
PYXSPyxis Oncology, Inc.LTM Mar 2026$27K ——0.2%
ZURAZura Bio LimitedLTM Mar 2026$16K +220.0%——
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$101K -104.8%-1.1%44.9%
Peer median (excluding NAUT) $1M+85.4%+13.1%22.8%

Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue2.84M3.42M5.71M6.35M6.47M
Gross Profit(2.84M)(3.42M)(5.71M)(6.35M)(6.47M)
Gross Margin—————
Research & Development26.51M36.46M47.25M50.48M41.11M
Selling, General & Admin21.15M23.75M28.9M31M25.73M
Operating Expenses47.66M60.2M70.45M75.12M60.37M
Depreciation & Amortization2.84M3.42M1.85M6.35M6.47M
EBITDA(47.47M)(54.51M)(61.83M)(64.43M)(52.54M)
EBITDA Margin—————
Operating Income(50.5M)(63.62M)(76.15M)(81.48M)(66.84M)
Operating Margin—————
Interest Income329K5.82M12.55M10.78M7.87M
Interest Expense05.82M000
Other Income / Expenses183K5.69M12.48M10.7M7.84M
Income Before Tax(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Net Margin—————
EPS (Basic)(0.60)(0.46)(0.51)(0.56)(0.47)
EPS (Diluted)(0.60)(0.46)(0.51)(0.56)(0.47)
Weighted Avg Shares84.46M124.59M124.92M125.43M126.26M
Weighted Avg Shares (Diluted)84.46M124.59M124.92M125.43M126.26M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Intrinsic Alpha fair value

Locked

Current Price

$2.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.